#USA #pancreatic cancer #South San Francisco #Human Longevity #Avantect

Human Longevity, Inc. Expands Cancer Prevention Offering

Human Longevity, Inc. (HLI), recognized as a global leader in precision health and longevity medicine, has recently announced an exciting advance in cancer prevention as it integrates the ClearNote Health Avantect® Pancreatic Cancer Test into its offerings. This innovative test is designed to detect early-stage pancreatic cancer, a type of cancer notorious for its late diagnosis and high mortality rate.

Revolutionizing Early Cancer Detection

The Avantect test stands out due to its DNA-based technology, utilizing a straightforward blood draw to reveal vital health information. It focuses on identifying significant epigenomic changes, specifically tracking 5-hydroxymethylcytosine (5hmC) markers, which signal potential early-stage pancreatic cancer. This makes the Avantect test particularly crucial for patients deemed at high risk, including individuals over the age of 50 who have recently developed type 2 diabetes, along with those with relevant family histories or genetic predispositions. The test has demonstrated impressive results, boasting a sensitivity of 68.3% and specificity of 96.9% for early disease detection.

Powerful Integration of Technologies

What sets Human Longevity apart is its multimodal approach combining Avantect's epigenomic technology with HLI's proprietary whole genome sequencing, which analyzes over three billion base pairs per patient, identifying genetic predispositions and early physiological changes. Additionally, HLI employs state-of-the-art MRI imaging tailored to enhance pancreatic visualization, further augmenting the early detection process.

Dr. Wei-Wu He, Executive Chairman of HLI, emphasized the mission: "Our goal is to detect disease before it becomes life-threatening. Early detection, specifically for challenging cancers like pancreatic, is crucial for improving outcomes. By merging the innovative technology of Avantect with our advanced genomic and imaging capabilities, we are paving the way for early intervention strategies."

A New Standard in Health Management

David Mullarkey, CEO of ClearNote Health, expressed enthusiasm about the partnership with HLI, stating, "We are proud to collaborate with Human Longevity to deliver the Avantect test, enhancing proactive health management for our clients. Together, we are reimagining what's possible in early pancreatic cancer detection, giving individuals a greater opportunity to change their health trajectories."

The Avantect test will initially be accessible to HLI's executive health clients who are currently engaged in extensive wellness programs. Efforts will be concentrated on those at higher risk, including individuals with new-onset diabetes, BRCA2 mutations, or established family histories of pancreatic cancer. This initiative reflects HLI's broader commitment to proactive health care and early detection of preventable diseases., including its recent pledge of $1 million to any client diagnosed with late-stage prostate cancer while under continuous care with HLI.

Envisioning a Healthier Future

Human Longevity's vision revolves around empowering individuals with information and resources that facilitate disease prevention before symptoms manifest. The integration of the Avantect test represents a significant stride toward fulfilling this vision. As Dr. He notes, "Precision medicine is most impactful when it is applied early. Our clients seek knowledge about their health risks not after a diagnosis but before it occurs. With this comprehensive testing platform, we are delivering exactly what they need."

For further information about the integration of Avantect test and related health offerings, visit Human Longevity. HLI continues to redefine the landscape of health care, transitioning from a reactive model to one that emphasizes proactive and personalized approaches to health management.